- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2023 | Faculty of Medicine in Hradec Králové
- Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge2016 | Faculty of Medicine in Hradec Králové
- Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia2012 | Faculty of Medicine in Hradec Králové
- Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study2015 | Faculty of Medicine in Hradec Králové
- Alemtuzumab In Relapsing And Refractory Chronic Lymphocytic Leukemia. A single Centre ExperiencePublication without faculty affiliation
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia2010 | First Faculty of Medicine, Third Faculty of Medicine
- Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study2015 | First Faculty of Medicine, Third Faculty of Medicine
- Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results2022 | Faculty of Medicine in Hradec Králové
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Faculty of Medicine in Hradec Králové
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Ofatumumab treatment of fludarabine and alemtuzumab refractory patients2012 | Faculty of Medicine in Hradec Králové
- Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning2019 | Publication without faculty affiliation
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové
- Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 20152015 | First Faculty of Medicine
- Venetoclax - new drones to deploy against chronic lymphocytic leukemia2018 | Third Faculty of Medicine
- Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future2015 | First Faculty of Medicine
- Guidelines for alemtuzumab treatment in chronic lymphocytic leukemia (CLL)2012 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, First Faculty of Medicine
- Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT2017 | Publication without faculty affiliation
